Synthesis of amylose acetates and amylose sulfates with high structural uniformity.

Amylose triacetate (ATA) dissolved in DMSO was partially deacetylated by 1,6-hexamethylendiamine, 1,8-octamethylendiamine, 1,12-dodecylmethylendiamine and 1,2-cyclohexyldiamine (mixture of cis and trans isomers) at 80 degrees C. The reaction kinetics of the deacetylation were studied. Differences were found in the course of the reaction depending on the type of alkylene diamine (linear or cyclic). The isolated amylose acetates were dissolved in DMF and subsequently sulfated with sulfamic acid. In the course of the sulfation, the acetyl groups acted as protective groups and were completely cleaved after reaction. The amylose acetates and sulfates obtained were studied by 13C NMR spectroscopy and elemental analysis. It could be shown, that the deacetylation of ATA with the described alkylene diamines as well as the subsequent sulfation are highly regioselective. By proceeding this reaction scheme it is possible to synthesize 6-amyloseacetate, 2,6-di-amyloseacetate and 2-amylosesulfate with a high structural uniformity.

Encapsulated cells to focus the metabolic activation of anticancer drugs.

One of the first strategies for cancer gene therapy was the use of suicide gene/prodrug combinations, originally delivered to tumor cells using viral vectors. A major limitation of this approach was the inefficiency of suicide gene delivery. An alternative strategy, in which the suicide genes are physically juxtaposed to the tumor, involves the implantation of encapsulated, genetically modified cells. Cell encapsulation technologies were originally developed for the treatment of acquired and genetic diseases, such as diabetes. In the application of this technology for the treatment of tumors, cells that are genetically modified to overexpress suicide genes are encapsulated and implanted near solid tumors; this process is then followed by systemic prodrug administration. This review discusses the various cells types, suicide genes and prodrugs that have been used in preclinical and clinical trials, as well as the data that have been obtained from these studies. Future improvements for the production of second-generation approaches are also discussed.